TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33561018

Group type: EXPERIMENTAL
Intervention: Development of an exhaustive list of health-related quality of life (HRQoL) issues relevant to sarcoma patients and determination of content validity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategy for HRQoL measurement in sarcoma patients.
Number of subjects: 0
Study: 33561122

Group type: EXPERIMENTAL
Intervention: Whole egg consumption (additional half of a whole egg per day)
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake (additional 300 mg per day)
Number of subjects: 521120

Group type: COMPARATOR
Intervention: Egg white/substitute consumption
Number of subjects: 521120

Group type: COMPARATOR
Intervention: Replacing half a whole egg with egg whites/substitutes or other protein sources
Number of subjects: 521120
Study: 33561169

Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) infants
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 907
Study: 33561262

Group type: EXPERIMENTAL
Intervention: Cetuximab plus S-1 plus cisplatin
Number of subjects: 40
Study: 33561615

Group type: EXPERIMENTAL
Intervention: Appropriate-fitting footwear
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ill-fitting footwear
Number of subjects: 153
Study: 33562091

Group type: EXPERIMENTAL
Intervention: Rifamycin SV, 600 mg modified release tablets, taken three times a day for 14 days (total daily intake: 1800 mg)
Number of subjects: 18
Study: 33562419

Group type: EXPERIMENTAL
Intervention: Passive microwave radiometry (MWR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 0
Study: 33562569

Group type: EXPERIMENTAL
Intervention: let-7b-5p levels in cerebrospinal fluid (CSF)
Number of subjects: 0
Study: 33563002

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4200
Study: 33563015

Group type: EXPERIMENTAL
Intervention: Thrombectomy plus standard care
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 293
Study: 33563242

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback from the hippocampus
Number of subjects: 84

Group type: COMPARATOR
Intervention: Real-time fMRI neurofeedback from a functionally independent region
Number of subjects: 84
Study: 33563263

Group type: EXPERIMENTAL
Intervention: Difficulty engaging with doctors (1-4; higher score = greater difficulty)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Difficulty engaging with doctors
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: LEP status (yes vs. no)
Number of subjects: 304
Study: 33563768

Group type: EXPERIMENTAL
Intervention: Universal germline testing for cancer susceptibility genes
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Broad panel including genes from the additional testing set
Number of subjects: 486
Study: 33563776

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed using the EuroQol-5 dimension (EQ-5D) questionnaire at enrolment and 6-month intervals.
Number of subjects: 9126
Study: 33563894

Group type: EXPERIMENTAL
Intervention: Panobinostat (10 or 15 mg), lenalidomide 15 mg, bortezomib 1 mg/m²
Number of subjects: 20
Study: 33564263

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily (QD)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily (BID)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study: 33564311

Group type: EXPERIMENTAL
Intervention: Combined external cold and vibrating devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 0
Study: 33565026

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg (Cohort 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg (Cohort 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lasmiditan (both cohorts)
Number of subjects: 18
Study: 33565042

Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam (M-V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available treatment (BAT)
Number of subjects: 0
Study: 33565427

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1343
Study: 33565790

Group type: EXPERIMENTAL
Intervention: Post-acute pancreatitis pancreatic exocrine insufficiency (PEI) assessment using fecal elastase-1
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 77
Study: 33565964

Group type: EXPERIMENTAL
Intervention: Transcriptional changes associated with multiple epidemiologic risk factors in cord blood mononuclear cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood serum concentration of PGLYRP-1.
Number of subjects: 0
Study: 33566467

Group type: EXPERIMENTAL
Intervention: Urinary (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) test
Number of subjects: 723
Study: 33566729

Group type: EXPERIMENTAL
Intervention: Diabetes technology use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 0
Study: 33567087

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific antibodies testing using VITROS Anti-SARS-CoV-2 IgG test
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Symptoms of anosmia/ageusia
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Symptoms of chest congestion
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Symptoms of fever
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Symptoms of shortness of breath
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Previous RT-PCR testing
Number of subjects: 566
Study: 33567109

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (lorazepam, midazolam, diazepam)
Number of subjects: 460
Study: 33567192

Group type: EXPERIMENTAL
Intervention: Unilateral vestibular implant (prosthesis)
Number of subjects: 9
Study: 33567333

Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam (C/T) 3 g (ceftolozane 2 g/tazobactam 1 g) as a 60-minute intravenous infusion
Number of subjects: 11
Study: 33568007

Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 221
Study: 33568158

Group type: EXPERIMENTAL
Intervention: High intake of vegetables
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Mediation by gut microbiome (Collinsella)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Habitual diet high in vegetables
Number of subjects: 986

Group type: COMPARATOR
Intervention: Fruit intake
Number of subjects: 986
Study: 33568188

Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds of ≥100 steps/min
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Heuristic cadence thresholds of ≥130 steps/min
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds for moderate intensity
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds for vigorous intensity
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ROC analysis cadence thresholds for moderate intensity
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ROC analysis cadence thresholds for vigorous intensity
Number of subjects: 157
Study: 33568190

Group type: EXPERIMENTAL
Intervention: Prostate Membrane Specific Antigen (PSMA) positron emission tomography (PET) and multiparametric MRI (mpMRI)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adjuvant or salvage radiation therapy (PORT)
Number of subjects: 34
Study: 33568222

Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (TNBC) patients diagnosed before age 70, predominantly BRCA1-deficient cases (90% of 82 cases).
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Full TNBC cohort.
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: TNBC patients across different genetic subtypes.
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Public WGS data for other breast cancer subgroups.
Number of subjects: 237
Study: 33568344

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1), administered intravenously every 3 weeks until confirmed disease progression or loss of clinical benefit.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 35
Study: 33568345

Group type: EXPERIMENTAL
Intervention: Crizotinib at the recommended phase II dose of 280 mg/m²
Number of subjects: 20
Study: 33568350

Group type: EXPERIMENTAL
Intervention: Additional immune modulators (tumor necrosis factor-alpha inhibitor 77%, mycophenolate 23%) in addition to systemic steroids
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Additional immune modulators
Number of subjects: 26
Study: 33568360

Group type: EXPERIMENTAL
Intervention: Statin therapy (10.8% at baseline, 46.5% moderate-intensity, 4.6% high-intensity)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combined treatment (4.2% at baseline, increased to 41.6% at 3 months, decreased to 20.8% at 1 year, increased to 38.9% at 2 years)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Fibrates (8.3% at baseline)
Number of subjects: 288
Study: 33568367

Group type: EXPERIMENTAL
Intervention: L-POCUS (lung point-of-care ultrasonography) performed within 48 hours following ED admission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-POCUS score assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second L-POCUS performed at day 5±3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment as recommended by WHO
Number of subjects: 0
Study: 33568371

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (H-RP) including smoking cessation, nutritional support, physiotherapy (at least one session/week), and home cycle-ergometry (at least three times/week).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (H-RP) non-completion.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Polypharmacy (n=24).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Living alone (n=8).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Long delay before starting the H-RP (n=18).
Number of subjects: 50
Study: 33568372

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative assessment factors
Number of subjects: 0
Study: 33568403

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control subjects without diabetes
Number of subjects: 144
Study: 33569002

Group type: EXPERIMENTAL
Intervention: Proposed biosimilar BAT1806
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference Tocilizumab
Number of subjects: 0
Study: 33569214

Group type: EXPERIMENTAL
Intervention: Etoposide capsules (25 mg/50 mg) as maintenance therapy, once a day for 20 days, every 28 days until disease progression.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Observation (non-maintenance therapy, NMT) group.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Etoposide capsules (25 mg) in stage I.
Number of subjects: 92
Study: 33569305

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 33569311

Group type: EXPERIMENTAL
Intervention: RRx-001 treatment in combination with a platinum doublet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RRx-001 treatment
Number of subjects: 14
Study: 33569343

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study: 33569442

Group type: EXPERIMENTAL
Intervention: Capture-based targeted sequencing using various commercially-available panels
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Two- and three-tier classification systems based on TMB estimates
Number of subjects: 32
Study: 33569446

Group type: EXPERIMENTAL
Intervention: MF30 asymmetric refractive MIOLs
Number of subjects: 70

Group type: COMPARATOR
Intervention: ZMB00 all optic zone diffractive MIOLs
Number of subjects: 70
Study: 33569469

Group type: EXPERIMENTAL
Intervention: CCC-ACS score (new point-based risk score)
Number of subjects: 62546

Group type: EXPERIMENTAL
Intervention: CCC-ACS score
Number of subjects: 62546
Study: 33569494

Group type: EXPERIMENTAL
Intervention: BI 1265162 single doses ≤1200 µg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1265162 multiple doses of 600 µg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1265162
Number of subjects: 0
Study: 33569501

Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms Questionnaire (RSQ)
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: RSQ items
Number of subjects: 1530
Study: 33569563

Group type: EXPERIMENTAL
Intervention: Mental Component Score (MCS) for participants who later developed dementia (mean± SD: 53.9±9.5)
Number of subjects: 2746

Group type: COMPARATOR
Intervention: Physical Component Score (PCS) at baseline for dementia (49.3±7.9) vs. non-dementia (49.8±7.8)
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: MCS as an indicator for eventual dementia diagnosis
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: 10-unit increase in MCS
Number of subjects: 2746
Study: 33569703

Group type: EXPERIMENTAL
Intervention: Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cytomorphological evaluation of bone marrow aspirate
Number of subjects: 62
Study: 33569981

Group type: EXPERIMENTAL
Intervention: Pictorial information regarding patients' subclinical atherosclerosis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pictorial information and written information regarding atherosclerosis and CVD risk
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pictorial information about carotid ultrasound results
Number of subjects: 15
Study: 33569983

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study: 33570247

Group type: EXPERIMENTAL
Intervention: Combination of PARP inhibitor (PARPi) and EZH2 inhibitor
Number of subjects: 0
Study: 33570423

Group type: EXPERIMENTAL
Intervention: Novel Motor-Driven Endoscopic Ablation System
Number of subjects: 0
Study: 33570583

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (specific micronutrients not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrient fortification programs (not detailed)
Number of subjects: 0
Study: 33570641

Group type: EXPERIMENTAL
Intervention: DICER1 carriers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DICER1 carriers and family controls
Number of subjects: 0
Study: 33571163

Group type: EXPERIMENTAL
Intervention: CCR5 gene-edited CD4+ T cells (infused 10 billion cells)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CCR5 gene-edited CD4+ T cells
Number of subjects: 14
Study: 33571166

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone and mirabegron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 0
Study: 33571215

Group type: EXPERIMENTAL
Intervention: Ocular Hypertension (OHT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pre-perimetric primary open-angle glaucoma (pre-POAG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups (OHT, pre-POAG, controls)
Number of subjects: 180
Study: 33571265

Group type: EXPERIMENTAL
Intervention: Face-to-face individual semi-structured interviews with GPs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Utilisation of diagnostic testing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perceptions on the introduction of rapid point-of-care tests
Number of subjects: 20
Study: 33571362

Group type: EXPERIMENTAL
Intervention: Daily growth hormone treatment
Number of subjects: 37702
Study: 33571450

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in children
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in daycare centre staff
Number of subjects: 688

Group type: COMPARATOR
Intervention: SARS-CoV-2 seroprevalence in comparator group
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Estimated SARS-CoV-2 infection in children
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Estimated SARS-CoV-2 infection in daycare centre staff
Number of subjects: 688

Group type: COMPARATOR
Intervention: Estimated SARS-CoV-2 infection in comparator group
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Exploratory analysis of seropositive children exposure
Number of subjects: 688
Study: 33571520

Group type: EXPERIMENTAL
Intervention: Neogenin expression in DIPG tumors, specific dosage and duration not available
Number of subjects: 0
Study: 33571930

Group type: EXPERIMENTAL
Intervention: Pain in PLWD
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Caregiver upset with NPS
Number of subjects: 272
Study: 33573594

Group type: EXPERIMENTAL
Intervention: Peer-led exercise program, twice a week for 12 weeks, led by a trained leader of the same age.
Number of subjects: 31
Study: 33573648

Group type: EXPERIMENTAL
Intervention: Long-term residential exposure to air pollution (fine particulate matter, PM)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Residential access to neighborhood greenspaces
Number of subjects: 133
Study: 33573693

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction combined with a Mediterranean diet (IER + MED)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dietary Approaches to Stop Hypertension (DASH) diet
Number of subjects: 59
Study: 33573694

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) parenting program for 19 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study: 33573748

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33573885

Group type: EXPERIMENTAL
Intervention: COVID-19 prevention strategies in long-term care facilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GeroCovid Observational Study
Number of subjects: 0
Study: 33573928

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 132
Study: 33574022

Group type: EXPERIMENTAL
Intervention: EF1 above the median in asymptomatic patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: EF1 above the median in patients with discordant AS
Number of subjects: 202
Study: 33574078

Group type: EXPERIMENTAL
Intervention: 22-gene RNA model (TB22)
Number of subjects: 222
Study: 33574140

Group type: EXPERIMENTAL
Intervention: Gut microbiome composition analysis using 16S ribosomal RNA sequencing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of arterial stiffness using cf-PWV, CAVI, ba-PWV, and Ankle-Brachial Index.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle assessment through food frequency questionnaire, Mediterranean diet adherence, and IPAQ.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body composition evaluation by bioimpedance.
Number of subjects: 0
Study: 33574446

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT) with a dose of 50 Gy (25 fractions of 2 Gy over 5 weeks)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 288
Study: 33574663

Group type: EXPERIMENTAL
Intervention: Early re-exacerbation (1-90 days)
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Late re-exacerbation (91-180 days)
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: No re-exacerbation within 180 days
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Factors predictive of re-exacerbation
Number of subjects: 1420

Group type: EXPERIMENTAL
Intervention: Prolonged AECOPDs
Number of subjects: 1420
Study: 33574699

Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit (with Fitbit device)
Number of subjects: 82

Group type: COMPARATOR
Intervention: GetActive (without Fitbit device)
Number of subjects: 82
Study: 33574792

Group type: EXPERIMENTAL
Intervention: Stenting for symptomatic intracranial artery stenosis
Number of subjects: 0
Study: 33574900

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) combined with cisplatin-based chemoradiation (CCRT)
Number of subjects: 10
Study: 33574913

Group type: EXPERIMENTAL
Intervention: Sitagliptin combined with metformin (Sig)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Insulin therapy (Ins)
Number of subjects: 168
Study: 33575025

Group type: EXPERIMENTAL
Intervention: ASPECTS assessment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ASPECTS cutoff value
Number of subjects: 150
Study: 33575322

Group type: EXPERIMENTAL
Intervention: PEGylated-interferon (PEG-IFN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entecavir therapy
Number of subjects: 0
Study: 33575428

Group type: EXPERIMENTAL
Intervention: Women with HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 0
Study: 33575683

Group type: EXPERIMENTAL
Intervention: Video-counseling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33575971

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (positive psychology-motivational interviewing)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Early increase cutoffs of 500 and 2000 steps
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Variability in early steps
Number of subjects: 52
Study: 33576064

Group type: EXPERIMENTAL
Intervention: Smarthealth technology
Number of subjects: 30
Study: 33576249

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 33576388

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in LFLG-AS patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in LFLG-AS patients with high likelihood of true-severe AS
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) in LFLG-AS patients with intermediate likelihood of true-severe AS
Number of subjects: 202

Group type: COMPARATOR
Intervention: High-gradient aortic stenosis (AS) patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: LFLG-AS patients with high likelihood of true-severe AS
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: LFLG-AS patients with intermediate likelihood of true-severe AS
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Criteria for treatment futility
Number of subjects: 202